Android app on Google Play

AVEO Pharma (AVEO) to Present Data from Tivozanib at AACR 12

March 27, 2012 6:37 AM EDT Send to a Friend
AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

For the schedule, click here.

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment